Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells.
Norcantharidin (NCTD), a chemically modified form of cantharidin, is a potential anticancer drug. This study investigated the effect of NCTD on anoikis in CT26 colorectal adenocarcinoma cells. NCTD treatment of CT26 cells showed a dose-dependent and time-dependent decrease in viability and cell proliferation. Growth inhibition was accompanied by cell cycle arrest in the S and G2/M phases. Mitogen-activated protein kinase expression, assayed by Western blot, was unchanged except for Jun-N-terminal kinase (JNK). At 24 h of treatment with 0-20 micromol/l NCTD, JNK expression increased at 24 h, but then decreased at 48 h; in contrast, the phosphorylated JNK levels markedly increased. JNK inhibitor (SP600125) in the culture effectively blocked NCTD-induced cytotoxicity and detachment of cells. CT26 cells treated with NCTD not only displayed inhibited cell adhesion and down-expression of integrin beta1, but also changed from being shuttle-shaped to round, the latter cells being more susceptible to anoikis-mediated apoptosis. Flow cytometric assay of the DNA content in NCTD-treated CT26 cells at 24 and 48 h showed a marked increase in the sub-G1 level, indicating that NCTD induced apoptosis. NCTD inhibited the viability of CT26 cancer cells preferentially over normal bone marrow and mononuclear cells. NCTD inhibits CT26 cancer cells by blocking proliferation and inducing anoikis-mediated apoptosis, a process that might be regulated by JNK activation.
Chen
Yu-Jen
YJ
Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan.
Kuo
Cheng-Deng
CD
Tsai
Yin-Meng
YM
Yu
Chih-Chia
CC
Wang
Guang-Sheng
GS
Liao
Hui-Fen
HF
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D023102:Anoikis / Q000187:drug effects*; D000963:Antimetabolites; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D001854:Bone Marrow Cells / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D001973:Bromodeoxyuridine; D002448:Cell Adhesion / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003627:Data Interpretation, Statistical; D004789:Enzyme Activation / Q000187:drug effects; D005434:Flow Cytometry; D048031:JNK Mitogen-Activated Protein Kinases / Q000096:biosynthesis / Q000378:metabolism*; D051379:Mice; D009000:Monocytes / Q000187:drug effects
D000963:Antimetabolites; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; C069741:norcantharidin; D048031:JNK Mitogen-Activated Protein Kinases; D001973:Bromodeoxyuridine